Adaptive Biotechnologies Corp (NASDAQ: ADPT)

$13.35 ▼ -0.19 (-1.37%)

As of May 12, 2026 12:11 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001478320

Market Cap 2.14 Bn

P/E -35.23

P/S 7.72

Div. Yield 0.00

Total Debt (Qtr) 131.21 Mn

Revenue Growth (1y) (Qtr) 51.04

Add ratio to table...

About

Adaptive Biotechnologies Corporation decodes the adaptive immune system to transform disease diagnosis and treatment. The company specializes in immune medicine, leveraging proprietary technologies to sequence, map, and characterize T-cell and B-cell receptors at scale. Its platform combines next-generation sequencing, computational biology, and machine learning to generate clinical immunomics data, enabling the development of precision diagnostics and therapeutics for cancer and autoimmune diseases. The company generates revenue through clinical...

Adaptive Biotechnologies Corporation decodes the adaptive immune system to transform disease diagnosis and treatment. The company specializes in immune medicine, leveraging proprietary technologies to sequence, map, and characterize T-cell and B-cell receptors at scale. Its platform combines next-generation sequencing, computational biology, and machine learning to generate clinical immunomics data, enabling the development of precision diagnostics and therapeutics for cancer and autoimmune diseases.

The company generates revenue through clinical diagnostic testing and partnerships with biopharmaceutical firms. Its flagship product, clonoSEQ, is an FDA-authorized next-generation sequencing assay for minimal residual disease detection in lymphoid malignancies, sold directly to clinicians and used in drug development trials. The Immune Medicine business monetizes proprietary datasets, immune receptor sequencing services, and target discovery capabilities through licensing agreements and collaborations with pharmaceutical companies.

The company operates through the following segments:

• MRD Business: This segment focuses on minimal residual disease detection in hematologic cancers using the clonoSEQ assay. It serves clinicians for patient monitoring and biopharmaceutical partners for drug development, with clonoSEQ being the first and only FDA-authorized test for multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The segment also offers laboratory-developed tests for other lymphoid cancers, including diffuse large B-cell lymphoma and mantle cell lymphoma.

• Immune Medicine Business: This segment leverages the company’s immunosequencing platform to sequence, pair, and characterize T-cell and B-cell receptors. It provides immune receptor sequencing services, licenses proprietary datasets matching TCRs to antigens, and offers TCR-antigen prediction models and target discovery capabilities. The segment collaborates with pharmaceutical companies to accelerate therapeutic research in autoimmune diseases and oncology.

Adaptive Biotechnologies Corporation holds a leading position in immune medicine, distinguished by its proprietary immunosequencing platform and clinical immunomics database. Its clonoSEQ assay is the only FDA-authorized next-generation sequencing test for minimal residual disease in lymphoid malignancies, offering industry-leading sensitivity of one cancer cell per million. The company’s competitive advantages include a robust intellectual property portfolio, regulatory expertise, and a growing dataset of over 5 million TCR-antigen matches. Key competitors include companies developing flow cytometry-based MRD tests, circulating tumor DNA assays, and other immune profiling technologies, though none match Adaptive’s scale or clinical validation.

The company serves a diverse customer base, including hematologists, oncologists, and biopharmaceutical companies. Its clonoSEQ test is used in over 180 clinical trials conducted by more than 40 biopharmaceutical partners, including Pfizer. The Immune Medicine segment collaborates with pharmaceutical firms to advance drug discovery and development in autoimmune diseases and oncology. Additionally, the company’s diagnostic services are utilized by hospitals, cancer centers, and community clinics across the United States.

Investment thesis

Bull case

Adaptive’s MRD segment has demonstrated a resilient growth engine, as evidenced by a 46% revenue increase in 2025 and an expanding backlog of $210 million. The company’s aggressive focus on blood‑based testing, which now accounts for nearly half of all clonoSEQ volumes, signals a significant shift toward a less invasive, more scalable diagnostic model. Coupled with robust EMR integrations, especially through Flatiron, the firm is positioning itself to capture an ever larger share of community and academic sites, thereby smoothing seasonal volatility. This dual expansion of test volume and payer coverage is expected to lift ASP toward the $1,400 target in 2026, driving margin improvements toward 70% and enhancing overall profitability.
The firm’s strategic pivot to high‑throughput NovaSeq X+ sequencing has materially reduced per‑sample costs while enabling a higher test throughput that supports the projected 30% volume growth for 2026. By scaling production efficiency, Adaptive has moved from a 66% gross margin in 2025 to an anticipated 75% in the next fiscal year, setting the stage for a durable high‑margin profile. These improvements are compounded by a disciplined operating expense policy that has already slashed total costs by 2% YoY, reinforcing the company’s ability to absorb price pressures without compromising profitability. In a market where test costs are highly leveraged, such cost discipline offers a competitive advantage that will likely translate into higher market share.
Adaptive’s Immune Medicine (IM) unit, while still a minority revenue driver, is creating a new, high‑barrier data asset that could unlock significant future value. The partnership with a major pharmaceutical house to license TCR antigen data for AI modeling and target discovery illustrates that the company’s proprietary dataset has tangible utility beyond its current scope. The IM pipeline’s focus on autoimmune disease and the early success of a preclinical ankylosing spondylitis program underscore potential therapeutic collaborations that could generate breakthrough revenue streams once the company refocuses capital toward data generation and AI modeling. As the data set expands to over five million paired TCRs, the company is building an ecosystem that could attract additional pharmaceutical partners and position Adaptive as a central node in immuno‑diagnostics and therapeutic development.
The firm’s contractual relationships with a diversified set of national payers—including recent agreements with Anthem, Centene, and Florida—provide a robust foundation for ASP growth and payer coverage expansion. The company’s proactive renegotiation strategy, which has already improved collections by 74% YoY, signals strong commercial execution that can translate into higher realized prices. Moreover, the anticipated inclusion of MRD in new National Comprehensive Cancer Network guidelines across multiple indications is expected to cement clonoSEQ’s clinical relevance, thereby encouraging broader adoption among both academic and community practitioners. This alignment with guideline evolution will likely sustain test volume growth and reinforce the company’s pricing trajectory.
Adaptive’s digital footprint, reinforced by the recent acquisition of an EMR partner, offers a compelling data pipeline that can be leveraged for both operational efficiencies and potential subscription‑style revenue models. By embedding its test ordering platform into clinicians’ workflows, the company reduces friction for test procurement, which can accelerate adoption of newer test modalities such as blood‑based MRD. The data generated through this ecosystem also enhances the predictive power of the company’s AI‑driven insights, providing a self‑reinforcing loop that could open additional monetization channels, such as consulting or analytics services for payers and manufacturers.

Adaptive’s MRD segment has demonstrated a resilient growth engine, as evidenced by a 46% revenue increase in 2025 and an expanding backlog of $210 million. The company’s aggressive focus on blood‑based testing, which now accounts for nearly half of all clonoSEQ volumes, signals a significant shift toward a less invasive, more scalable diagnostic model. Coupled with robust EMR integrations, especially through Flatiron, the firm is positioning itself to capture an ever larger share of community and academic sites, thereby smoothing seasonal volatility. This dual expansion of test volume and payer coverage is expected to lift ASP toward the $1,400 target in 2026, driving margin improvements toward 70% and enhancing overall profitability.
The firm’s strategic pivot to high‑throughput NovaSeq X+ sequencing has materially reduced per‑sample costs while enabling a higher test throughput that supports the projected 30% volume growth for 2026. By scaling production efficiency, Adaptive has moved from a 66% gross margin in 2025 to an anticipated 75% in the next fiscal year, setting the stage for a durable high‑margin profile. These improvements are compounded by a disciplined operating expense policy that has already slashed total costs by 2% YoY, reinforcing the company’s ability to absorb price pressures without compromising profitability. In a market where test costs are highly leveraged, such cost discipline offers a competitive advantage that will likely translate into higher market share.
Adaptive’s Immune Medicine (IM) unit, while still a minority revenue driver, is creating a new, high‑barrier data asset that could unlock significant future value. The partnership with a major pharmaceutical house to license TCR antigen data for AI modeling and target discovery illustrates that the company’s proprietary dataset has tangible utility beyond its current scope. The IM pipeline’s focus on autoimmune disease and the early success of a preclinical ankylosing spondylitis program underscore potential therapeutic collaborations that could generate breakthrough revenue streams once the company refocuses capital toward data generation and AI modeling. As the data set expands to over five million paired TCRs, the company is building an ecosystem that could attract additional pharmaceutical partners and position Adaptive as a central node in immuno‑diagnostics and therapeutic development.
The firm’s contractual relationships with a diversified set of national payers—including recent agreements with Anthem, Centene, and Florida—provide a robust foundation for ASP growth and payer coverage expansion. The company’s proactive renegotiation strategy, which has already improved collections by 74% YoY, signals strong commercial execution that can translate into higher realized prices. Moreover, the anticipated inclusion of MRD in new National Comprehensive Cancer Network guidelines across multiple indications is expected to cement clonoSEQ’s clinical relevance, thereby encouraging broader adoption among both academic and community practitioners. This alignment with guideline evolution will likely sustain test volume growth and reinforce the company’s pricing trajectory.
Adaptive’s digital footprint, reinforced by the recent acquisition of an EMR partner, offers a compelling data pipeline that can be leveraged for both operational efficiencies and potential subscription‑style revenue models. By embedding its test ordering platform into clinicians’ workflows, the company reduces friction for test procurement, which can accelerate adoption of newer test modalities such as blood‑based MRD. The data generated through this ecosystem also enhances the predictive power of the company’s AI‑driven insights, providing a self‑reinforcing loop that could open additional monetization channels, such as consulting or analytics services for payers and manufacturers.

Bear case

The company’s revenue growth is heavily reliant on the successful renegotiation of two large payer contracts that cover roughly 17% to 18% of clonoSEQ test volume; any delay or less favorable terms could dampen ASP progress and strain margin expectations. Management explicitly acknowledged a "level of execution risk" associated with these negotiations, underscoring that the firm’s 2026 pricing guidance is contingent on outcomes that are not yet finalized. In the event of renegotiation failure, the firm would need to rely on alternative pricing levers that may not fully compensate for lost revenue, potentially eroding the projected 70% gross margin.
The company’s near‑term cash burn is expected to peak in the first quarter of 2026 due to annual corporate bonus payouts, which could create a temporary liquidity squeeze. While Adaptive currently holds a healthy cash balance, this seasonal cash outflow coincides with the period when the company is also expected to execute significant sales force investments and expand its clinical trial pipeline. The overlap of high cash utilization and the need for additional operating capital could pressure the firm’s working capital and create a scenario where it must seek external financing or divert funds from growth initiatives, potentially compromising its strategic trajectory.
Adaptive’s MRD test volume is still concentrated in a few high‑volume indications, notably multiple myeloma and DLBCL, leaving substantial upside potential unexploited. However, the company’s penetration in these markets, especially DLBCL where it controls only about 3% of the opportunity, is modest and may be challenged by emerging competitors. The recent entrance of a flow‑cytometry based assay that claims comparable sensitivity could erode Adaptive’s market share, particularly in community settings where pricing pressure may favor lower‑cost alternatives. Even though the company argues that flow methods are less sensitive, the presence of a competitive product could stimulate demand for more affordable testing options, thereby compressing ASP.
The Immune Medicine unit, while conceptually attractive, remains a high‑burn, low‑revenue segment with an adjusted EBITDA loss of $31 million in 2025. The company’s strategy to halt further investment in a specific therapeutic program (ankylosing spondylitis) in favor of data generation indicates a shift away from direct product development. This pivot places the unit’s long‑term upside in the uncertain realm of data licensing, which is subject to the willingness of pharma partners to invest in proprietary datasets. If the market for such data does not materialize as expected, the company could face a stranded asset scenario, leading to a permanent underperformance of the IM unit.
Adaptive’s business model is heavily dependent on a narrow set of key contracts and a limited number of payer relationships. The termination of the Genentech collaboration eliminated a notable revenue stream and highlighted the firm’s vulnerability to the loss of strategic partnerships. This event underscores a broader risk that future collaborations could similarly be dissolved or fail to materialize, which would reduce both cash flow and credibility with potential partners. A sudden withdrawal of a partner could also affect the company’s market perception and pricing power, further challenging its growth prospects.

The company’s revenue growth is heavily reliant on the successful renegotiation of two large payer contracts that cover roughly 17% to 18% of clonoSEQ test volume; any delay or less favorable terms could dampen ASP progress and strain margin expectations. Management explicitly acknowledged a "level of execution risk" associated with these negotiations, underscoring that the firm’s 2026 pricing guidance is contingent on outcomes that are not yet finalized. In the event of renegotiation failure, the firm would need to rely on alternative pricing levers that may not fully compensate for lost revenue, potentially eroding the projected 70% gross margin.
The company’s near‑term cash burn is expected to peak in the first quarter of 2026 due to annual corporate bonus payouts, which could create a temporary liquidity squeeze. While Adaptive currently holds a healthy cash balance, this seasonal cash outflow coincides with the period when the company is also expected to execute significant sales force investments and expand its clinical trial pipeline. The overlap of high cash utilization and the need for additional operating capital could pressure the firm’s working capital and create a scenario where it must seek external financing or divert funds from growth initiatives, potentially compromising its strategic trajectory.
Adaptive’s MRD test volume is still concentrated in a few high‑volume indications, notably multiple myeloma and DLBCL, leaving substantial upside potential unexploited. However, the company’s penetration in these markets, especially DLBCL where it controls only about 3% of the opportunity, is modest and may be challenged by emerging competitors. The recent entrance of a flow‑cytometry based assay that claims comparable sensitivity could erode Adaptive’s market share, particularly in community settings where pricing pressure may favor lower‑cost alternatives. Even though the company argues that flow methods are less sensitive, the presence of a competitive product could stimulate demand for more affordable testing options, thereby compressing ASP.
The Immune Medicine unit, while conceptually attractive, remains a high‑burn, low‑revenue segment with an adjusted EBITDA loss of $31 million in 2025. The company’s strategy to halt further investment in a specific therapeutic program (ankylosing spondylitis) in favor of data generation indicates a shift away from direct product development. This pivot places the unit’s long‑term upside in the uncertain realm of data licensing, which is subject to the willingness of pharma partners to invest in proprietary datasets. If the market for such data does not materialize as expected, the company could face a stranded asset scenario, leading to a permanent underperformance of the IM unit.
Adaptive’s business model is heavily dependent on a narrow set of key contracts and a limited number of payer relationships. The termination of the Genentech collaboration eliminated a notable revenue stream and highlighted the firm’s vulnerability to the loss of strategic partnerships. This event underscores a broader risk that future collaborations could similarly be dissolved or fail to materialize, which would reduce both cash flow and credibility with potential partners. A sudden withdrawal of a partner could also affect the company’s market perception and pricing power, further challenging its growth prospects.

Consolidation Items Breakdown of Revenue (2025)

Plan Name Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools